Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS). Results: Overall, 564 patients were included (median follow-up: 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted. Conclusion: The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.

Barbara Ann Karmanos Cancer Institute Wayne State University School of Medicine Detroit MI 48201 USA

CHU de Bordeaux Bordeaux 33000 France

CHU de Caen Caen 14000 France

Department of Clinical Therapeutics National and Kapodistrian University of Athens School of Medicine Athens 115 27 Greece

Department of Haematology Oxford University Hospitals NHS Foundation Trust Oxford Oxfordshire OX3 7LE UK

Institute of Biostatistics and Analyses Ltd Brno 602 00 Czech Republic

M D Anderson Cancer Center Houston TX 77030 USA

Pôle Régional de Cancérologie Department of Hematology CHU La Milétrie Poitiers Poitiers 86000 France

Takeda Development Center Americas Inc Lexington MA 02421 USA

Takeda Pharmaceuticals International AG Opfikon 8152 Switzerland

Takeda Pharmaceuticals U S A Inc Lexington MA 02421 USA

Citace poskytuje Crossref.org